NDA 217836 · Orasis Pharms
Qlosi
Pilocarpine Hydrochloride · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Oct 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 17, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
21 Phase 3, 2 recruiting
FAERS reports
1,260
645 serious, 34 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2026.
QLOSI is indicated for the treatment of presbyopia in adults. QLOSI is a cholinergic agonist indicated for the treatment of presbyopia in adults. ( 1 )
Mechanism: Pilocarpine hydrochloride is a cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle. QLOSI contracts the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near visual acuity while maintaining some pupillary response to light.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- QLOSI · PILOCARPINE HYDROCHLORIDE 0.4% · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pilocarpine" as an intervention, any sponsor and status, largest first.
- A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03857542 · 427 participants · Start Mar 1, 2019 · Primary completion Sep 10, 2020
Drug: Pilocarpine HCl Ophthalmic Solution · For: Presbyopia
Sites: Dothan, Alabama; Prescott, Arizona; Sun City, Arizona · 35 sites in all
- Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OABPivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT02485067 · 384 participants · Start Jan 2015 · Primary completion Jul 2016
Drug: THVD-201; Placebo(For THVD-201) and 2 more · For: Overactive Bladder
Sites: Busan, South Korea; Cheonan, South Korea; Gwangju, South Korea · 16 sites in all
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05646719 · 333 participants · Start Dec 22, 2022 · Primary completion Oct 11, 2023
Drug: Phentolamine Opthalmic Solution 0.75%; Low dose pilocarpine · For: Presbyopia
Sites: Phoenix, Arizona; Azusa, California; Newport Beach, California · 26 sites in all
- Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With PresbyopiaPivotal-lookingStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06451666 · 330 participants (planned) · Start Jun 30, 2024 · Primary completion Nov 30, 2025
Drug: Pilocarpine HCl Ophthalmic Solution; Vehicle · For: Presbyopia
- Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03804268 · 323 participants · Start Dec 21, 2018 · Primary completion Oct 31, 2019
Drug: Pilocarpine HCl Ophthalmic Solution · For: Presbyopia
Sites: Chandler, Arizona; Scottsdale, Arizona; Beverly Hills, California · 36 sites in all
- An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)Pivotal-lookingCompleted
Orasis Pharmaceuticals Ltd.Industry
NCT04599933 · 309 participants · Start Oct 18, 2020 · Primary completion Feb 11, 2022
Drug: CSF-1; Vehicle · For: Presbyopia
Sites: Sun City, Arizona; Glendale, California; Los Angeles, California · 17 sites in all
- An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)Pivotal-lookingCompleted
Orasis Pharmaceuticals Ltd.Industry
NCT04599972 · 304 participants · Start Oct 26, 2020 · Primary completion Jan 21, 2022
Drug: CSF-1; Vehicle · For: Presbyopia
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 18 sites in all
- The International Collaborative Exfoliation Syndrome Treatment StudyPivotal-lookingStatus unknown
The New York Eye & Ear InfirmaryAcademic, hospital or other
NCT00804115 · 277 participants · Start Aug 2000 · Primary completion Sep 2007
Drug: Latanoprost with Pilocarpine vs Timolol or Cosopt · For: Exfoliation Syndrome; Glaucoma; Ocular Hypertension
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective143
- headache104
- fatigue97
- pain96
- eye pain91
- dyspnoea85
- nausea80
- dizziness76
- diarrhoea74
- off label use70
- cough68
- fall67
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 20 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 15 |
| 2009 | 35 |
| 2010 | 43 |
| 2011 | 8 |
| 2012 | 14 |
| 2013 | 18 |
| 2014 | 15 |
| 2015 | 16 |
| 2016 | 7 |
| 2017 | 29 |
| 2018 | 40 |
| 2019 | 77 |
| 2020 | 93 |
| 2021 | 68 |
| 2022 | 119 |
| 2023 | 107 |
| 2024 | 140 |
| 2025 | 216 |
| 2026 | 152 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neurosteroids and Seizure Activity.
Miziak B, Chrościska-Krawczyk M, Czuczwar SJ · Front Endocrinol (Lausanne) 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
Waring GO, Price FW, Wirta D, et al. · JAMA Ophthalmol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance.
Waring GO, Brujic M, McGee S, et al. · Clin Exp Optom 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Miotics in closed-angle glaucoma.
Ganias F, Mapstone R · Br J Ophthalmol 1975 · Clinical Trial, Comparative Study
- Pupillometry in Chagas disease.
Vargas D, Castro C · Arq Bras Oftalmol 2018 · Clinical Trial
- Two decades of research towards a potential first anti-epileptic drug.
Benassi SK, Alves JGSM, Guidoreni CG, et al. · Seizure 2021 · Randomized Controlled Trial
Sponsor: Orasis Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.